Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.46 |
| ▸ | PDE4A | P27815 | 5/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15733793 | 0.80 | GRM5 (0.59) | PDE10APDE4BPDE3BPDE3A | |
| SCHEMBL30123501 | 0.80 | GRM5 (0.59) | PDE10APDE4BPDE3BPDE3A | |
| SCHEMBL4724002 | 0.80 | BRAF (0.53) | BRAFMAPK3MAPK1PDE10APDE4B | |
| SCHEMBL15022079 | 0.79 | PDE10A (0.51) | PDE10APDE4BPDE4APDE3BPDE3A | |
| SCHEMBL7106124 | 0.78 | CYP1A1 (0.61) | PDE10ACYP11B2 | |
| SCHEMBL15745978 | 0.78 | CYP1A1 (0.44) | CYP11B2 | |
| SCHEMBL15745979 | 0.74 | PDE10A (0.66) | BRAFMAPK3MAPK1PDE10A | |
| SCHEMBL8119242 | 0.73 | PRMT5 (0.48) | BRAFMAPK3MAPK1PDE10APDE4B | |
| SCHEMBL7690758 | 0.70 | — | — | |
| SCHEMBL10508644 | 0.69 | HIF1A (0.53) | MAPK1PDE10APDE4BPDE4APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-02-01 | — | — | US | disclosed |
| US-9790203-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | BRAF 3177/4885MAPK3 2268/4885MAPK1 957/4885 |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | BRAF 3150/4885MAPK3 2273/4885MAPK1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.